| This week's sponsor is TD2. | |  | |
Featured Story | | | Thursday, September 28, 2017 Novartis and UC Berkeley have formed a new pact aimed at unlocking difficult drug targets and boosting development of new meds in infectious diseases and cancer. |
|
|
| This week's sponsor is FierceBiotech. | |  | FierceBiotech Executive Summit- London
Join FierceBiotech for our third annual Executive Summit in London. We'll gather the experts together to discuss innovation around R&D in the UK and look ahead to what's in store for 2018 with leaders in the field discussing trends in the industry. |
Top Stories Thursday, September 28, 2017 A phase 2 trial of Zynerba Pharmaceuticals’ Fragile X syndrome drug met its primary endpoint. The beleaguered biotech’s stock doubled on news of the route to redemption, despite the study’s lack of a control arm leaving reason to question how big an effect the drug had on the patients. Thursday, September 28, 2017 Three biotech companies focusing on cancer and eye diseases have collectively raised more than $300 million. Monday, September 25, 2017 RBM shouldn’t be a point of concern, but rather a point of validation of what matters. It’s, above all, an opportunity to practice mindfulness in collecting clinical trial data within the site-and patient-centric environment. Thursday, September 28, 2017 Arcturus Therapeutics is set to gain a Nasdaq listing through a reverse merger with Alcobra. The deal will give Arcturus a route to public investors at a time when interest in RNA therapies is flying high on the back of Alnylam’s phase 3 success. Wednesday, September 27, 2017 As the opioid crisis broadens by the day, the biotech community is doubling down on its efforts to solve the mystery of addiction—and find new ways to combat it. Toward that end, two sets of researchers announced progress this week advancing research aimed at targeting addiction centers in the brain. Thursday, September 28, 2017 Through this brief summary of some presentations made by biopharma executives at this year’s Drug Development Forum, we offer some practical advice for sponsors on how to manage a smooth outsourcing relationship, and, for CROs, a peek into sponsors’ decision-making processes. Thursday, September 28, 2017 It didn't take long for Congress to push back at Allergan's first-of-a-kind patent deal with the Saint Regis Mohawk Tribe. Four senators are demanding an investigation, saying the move to protect Restasis is another example of pharma "putting profits before patients." | This week's sponsor is CMed. | |  | |
Resources Sponsored by: Veeva Systems The 2017 Unified Clinical Operations Survey finds that 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Presented By: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented By: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented By: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored by: Ashfield Healthcare Join this webinar to learn how to design, deliver, and measure a successful patient support program. Presented by Nareda Mills, Ashfield's SVP of Patient Services in the US, you’ll discover how to improve adherence and improve patient outcomes using 5 key methods. Presented By: PRA Health Sciences Children participating in pediatric clinical trials are included in the contraceptive requirements applied to women of child-bearing potential, creating significant challenges for sponsors, parents, investigators and study staff. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. | 
